TET2 and myeloid neoplasm: Loss-of-function mutations in TET2 were first identified in myeloid malignancies (28, 29) but soon thereafter recurrent somatic mutations in TET2 were recognized in approximately 50-70% of AITL and other TFH-derived lymphomas (11–15).